Cogent Cost Of Revenue vs Total Revenue Analysis

COGT Stock

USD 5.87 0.24 4.26%

Cogent Biosciences financial indicator trend analysis is way more than just evaluating Cogent Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cogent Biosciences is a good investment. Please check the relationship between Cogent Biosciences Cost Of Revenue and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cogent Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Cogent Stock please use our How to Invest in Cogent Biosciences guide.

Cost Of Revenue vs Total Revenue

Cost Of Revenue vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cogent Biosciences Cost Of Revenue account and Total Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Cogent Biosciences' Cost Of Revenue and Total Revenue is -0.44. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Cogent Biosciences, assuming nothing else is changed. The correlation between historical values of Cogent Biosciences' Cost Of Revenue and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Cogent Biosciences are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Cost Of Revenue i.e., Cogent Biosciences' Cost Of Revenue and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.44

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Cogent Biosciences income statement and represents the costs associated with goods and services Cogent Biosciences provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Revenue

Total revenue comprises all receipts Cogent Biosciences generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Cogent Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cogent Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cogent Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Cogent Stock please use our How to Invest in Cogent Biosciences guide.At this time, Cogent Biosciences' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 2.09 in 2025, whereas Enterprise Value Multiple is likely to drop (2.78) in 2025.

	2022	2023	2024	2025 (projected)
Interest Income	4.0M	11.3M	18.1M	19.0M
Net Interest Income	4.0M	11.3M	18.1M	19.0M

Interest Income Net Interest Income

Cogent Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Common Stock Total Equity	Short Term Investments	Property Plant And Equipment Gross	Inventory	Net Invested Capital
Total Assets		0.74	0.68	0.99	0.79	0.51	-0.41	-0.8	0.71	0.52	0.83	1.0	0.78	0.02	0.83	0.84	0.64	1.0	0.33	0.79	0.9	0.84	0.7	0.78	-0.32	0.9
Other Current Liab	0.74		0.98	0.69	0.88	0.86	0.02	-0.99	0.97	0.12	0.74	0.71	0.98	0.0	0.92	0.98	0.94	0.71	0.29	0.99	0.73	0.94	0.9	0.91	-0.83	0.74
Total Current Liabilities	0.68	0.98		0.63	0.85	0.91	0.09	-0.97	0.95	0.04	0.72	0.65	0.95	-0.06	0.89	0.96	0.93	0.66	0.33	0.97	0.68	0.93	0.89	0.88	-0.82	0.73
Total Stockholder Equity	0.99	0.69	0.63		0.74	0.45	-0.5	-0.76	0.65	0.61	0.78	1.0	0.74	-0.05	0.82	0.8	0.57	1.0	0.39	0.75	0.87	0.81	0.64	0.73	-0.29	0.91
Property Plant And Equipment Net	0.79	0.88	0.85	0.74		0.65	0.12	-0.9	0.91	0.03	0.94	0.74	0.91	0.2	0.79	0.91	0.88	0.75	0.21	0.92	0.85	0.93	0.93	0.99	-0.56	0.8
Current Deferred Revenue	0.51	0.86	0.91	0.45	0.65		0.22	-0.83	0.86	-0.12	0.55	0.48	0.83	-0.02	0.68	0.8	0.86	0.49	0.14	0.82	0.52	0.73	0.83	0.7	-0.75	0.52
Net Debt	-0.41	0.02	0.09	-0.5	0.12	0.22		0.03	0.15	-0.99	0.12	-0.49	0.0	0.33	-0.32	-0.1	0.21	-0.48	-0.38	-0.03	-0.16	-0.09	0.24	0.13	-0.05	-0.32
Retained Earnings	-0.8	-0.99	-0.97	-0.76	-0.9	-0.83	0.03		-0.97	-0.17	-0.8	-0.77	-0.98	0.02	-0.94	-0.99	-0.92	-0.78	-0.33	-0.99	-0.8	-0.97	-0.9	-0.92	0.76	-0.8
Accounts Payable	0.71	0.97	0.95	0.65	0.91	0.86	0.15	-0.97		-0.01	0.81	0.67	0.98	0.12	0.85	0.95	0.95	0.68	0.17	0.97	0.78	0.92	0.95	0.94	-0.76	0.71
Cash	0.52	0.12	0.04	0.61	0.03	-0.12	-0.99	-0.17	-0.01		0.01	0.59	0.14	-0.32	0.45	0.24	-0.07	0.59	0.42	0.17	0.27	0.24	-0.1	0.02	-0.05	0.44
Non Current Assets Total	0.83	0.74	0.72	0.78	0.94	0.55	0.12	-0.8	0.81	0.01		0.78	0.8	0.21	0.67	0.81	0.74	0.78	0.19	0.8	0.9	0.84	0.85	0.91	-0.28	0.82
Cash And Short Term Investments	1.0	0.71	0.65	1.0	0.74	0.48	-0.49	-0.77	0.67	0.59	0.78		0.75	0.0	0.82	0.81	0.6	1.0	0.34	0.76	0.87	0.81	0.66	0.73	-0.31	0.89
Common Stock Shares Outstanding	0.78	0.98	0.95	0.74	0.91	0.83	0.0	-0.98	0.98	0.14	0.8	0.75		0.1	0.9	0.98	0.95	0.76	0.22	0.98	0.83	0.95	0.93	0.94	-0.77	0.75
Non Current Liabilities Total	0.02	0.0	-0.06	-0.05	0.2	-0.02	0.33	0.02	0.12	-0.32	0.21	0.0	0.1		-0.23	-0.06	0.3	-0.01	-0.88	0.01	0.2	-0.1	0.34	0.25	-0.01	-0.29
Other Current Assets	0.83	0.92	0.89	0.82	0.79	0.68	-0.32	-0.94	0.85	0.45	0.67	0.82	0.9	-0.23		0.96	0.76	0.82	0.53	0.93	0.74	0.94	0.72	0.8	-0.73	0.85
Other Stockholder Equity	0.84	0.98	0.96	0.8	0.91	0.8	-0.1	-0.99	0.95	0.24	0.81	0.81	0.98	-0.06	0.96		0.89	0.82	0.38	0.99	0.81	0.98	0.88	0.92	-0.73	0.85
Total Liab	0.64	0.94	0.93	0.57	0.88	0.86	0.21	-0.92	0.95	-0.07	0.74	0.6	0.95	0.3	0.76	0.89		0.61	-0.01	0.93	0.71	0.85	0.97	0.93	-0.81	0.58
Total Current Assets	1.0	0.71	0.66	1.0	0.75	0.49	-0.48	-0.78	0.68	0.59	0.78	1.0	0.76	-0.01	0.82	0.82	0.61		0.34	0.77	0.88	0.82	0.66	0.74	-0.32	0.89
Short Term Debt	0.33	0.29	0.33	0.39	0.21	0.14	-0.38	-0.33	0.17	0.42	0.19	0.34	0.22	-0.88	0.53	0.38	-0.01	0.34		0.31	0.19	0.45	-0.02	0.14	-0.14	0.63
Common Stock	0.79	0.99	0.97	0.75	0.92	0.82	-0.03	-0.99	0.97	0.17	0.8	0.76	0.98	0.01	0.93	0.99	0.93	0.77	0.31		0.79	0.98	0.91	0.94	-0.76	0.81
Non Currrent Assets Other	0.9	0.73	0.68	0.87	0.85	0.52	-0.16	-0.8	0.78	0.27	0.9	0.87	0.83	0.2	0.74	0.81	0.71	0.88	0.19	0.79		0.82	0.78	0.84	-0.33	0.79
Common Stock Total Equity	0.84	0.94	0.93	0.81	0.93	0.73	-0.09	-0.97	0.92	0.24	0.84	0.81	0.95	-0.1	0.94	0.98	0.85	0.82	0.45	0.98	0.82		0.85	0.93	-0.66	0.9
Short Term Investments	0.7	0.9	0.89	0.64	0.93	0.83	0.24	-0.9	0.95	-0.1	0.85	0.66	0.93	0.34	0.72	0.88	0.97	0.66	-0.02	0.91	0.78	0.85		0.96	-0.67	0.65
Property Plant And Equipment Gross	0.78	0.91	0.88	0.73	0.99	0.7	0.13	-0.92	0.94	0.02	0.91	0.73	0.94	0.25	0.8	0.92	0.93	0.74	0.14	0.94	0.84	0.93	0.96		-0.63	0.76
Inventory	-0.32	-0.83	-0.82	-0.29	-0.56	-0.75	-0.05	0.76	-0.76	-0.05	-0.28	-0.31	-0.77	-0.01	-0.73	-0.73	-0.81	-0.32	-0.14	-0.76	-0.33	-0.66	-0.67	-0.63		-0.33
Net Invested Capital	0.9	0.74	0.73	0.91	0.8	0.52	-0.32	-0.8	0.71	0.44	0.82	0.89	0.75	-0.29	0.85	0.85	0.58	0.89	0.63	0.81	0.79	0.9	0.65	0.76	-0.33

Click cells to compare fundamentals

Cogent Biosciences Account Relationship Matchups

Cogent Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	250.9M	232.1M	300.8M	313.4M	327.9M	195.8M
Other Current Liab	8.3M	8.9M	18.2M	26.1M	42.1M	44.2M
Total Current Liabilities	13.1M	17.1M	26.8M	38.2M	55.7M	58.5M
Total Stockholder Equity	234.7M	214.2M	255.7M	257.8M	256.3M	160.7M
Property Plant And Equipment Net	4.7M	4.5M	31.1M	30.3M	26.6M	27.9M
Current Deferred Revenue	3.8M	8.0M	1.7M	25.7M	29.5M	31.0M
Net Debt	(237.0M)	(216.5M)	(120.2M)	(34.4M)	(80.7M)	(84.7M)
Retained Earnings	(198.7M)	(271.0M)	(411.2M)	(603.6M)	(859.5M)	(816.5M)
Accounts Payable	732K	3.5M	5.8M	10.7M	12.0M	12.6M
Cash	242.2M	219.7M	139.9M	53.2M	98.2M	110.7M
Non Current Assets Total	6.0M	9.5M	35.8M	42.7M	31.4M	17.1M
Cash And Short Term Investments	242.2M	219.7M	259.3M	265.7M	287.1M	174.9M
Common Stock Shares Outstanding	11.1M	38.7M	58.7M	79.7M	103.9M	109.0M
Liabilities And Stockholders Equity	250.9M	232.1M	300.8M	313.4M	327.9M	195.8M
Non Current Liabilities Total	3.2M	831K	18.2M	17.5M	15.9M	11.3M
Other Current Assets	5.4M	5.9M	5.7M	5.1M	9.4M	9.9M
Other Stockholder Equity	322.5M	399.7M	601.2M	801.1M	1.0B	1.1B
Total Liab	16.2M	17.9M	45.1M	55.6M	71.6M	75.2M
Total Current Assets	244.9M	222.6M	265.0M	270.8M	296.5M	178.7M
Short Term Debt	4.1M	4.6M	2.8M	1.4M	1.6M	2.8M
Common Stock	32K	44K	70K	86K	110K	115.5K
Property Plant And Equipment Gross	4.7M	5.0M	32.5M	34.0M	32.7M	34.3M
Net Invested Capital	123.8M	128.8M	189.9M	197.8M	145.7M	114.0M
Net Working Capital	231.8M	205.6M	238.1M	232.6M	240.8M	173.7M
Capital Stock	110.9M	85.4M	65.9M	60.1M	110.7M	68.1M
Short Long Term Debt Total	5.2M	3.2M	19.6M	18.9M	17.5M	12.9M
Capital Lease Obligations	5.2M	3.2M	19.6M	18.9M	17.5M	12.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Cogent Stock Analysis

When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC